Table 1 Clinical characteristics of cohorts used for training, testing and pilot validation of the methylation biomarkers
From: High performance methylated DNA markers for detection of colon adenocarcinoma
| Tissue | Training set | Test set | Plasma | Pilot set |
|---|---|---|---|---|
| Colon ca. (N) | 30 | 33 | Colorectal ca. (N) | 20 |
| Age at surgery (years) | Age (years) | |||
| Mean | 69 | 69 | Mean | 56 |
| Median | 68 | 69 | Median | 58 |
| Range | 55–86 | 56–85 | Range | 40–68 |
| Sex (N) | Sex (N) | |||
| Male | 11 | 19 | Male | 11 |
| Female | 19 | 14 | Female | 9 |
| Tumor cellularity (N) | ||||
| 0–40% | 2 | 1 | ||
| ≥ 40–70% | 17 | 16 | ||
| ≥ 70% | 11 | 16 | ||
| Stage | Stage | |||
| I | 7 | 11 | I | 0 |
| II | 11 | 15 | II | 0 |
| III | 12 | 7 | III | 0 |
| IV | 0 | 0 | IV | 20 |
| Location | Location of Primary | |||
| Colon ascendens | 14 | 18 | Colon ascendens | 9 |
| Colon transversum | 1 | 2 | Colon transversum | 0 |
| Colon descendens | 3 | 3 | Colon descendens | 2 |
| Sigmoid | 11 | 10 | Sigmoid | 7 |
| Rectum | 0 | 0 | Rectum | 2 |
| Not available | 1 | 0 | Not available | 0 |
| % Treated (N) | ||||
| Neoadjuvant | 0 (0) | 0 (0) | ||
| Adjuvant | 38.7 (12) | 20.6 (7) | ||
| Normal, adjacent (N) | 23 | 20 | Normal (N) | 20 |
| Age at surgery (years) | Age (years) | |||
| Mean | 66 | 65 | Mean | 70 |
| Median | 65 | 65 | Median | 70 |
| Range | 55–86 | 56–85 | Range | 26–97 |
| Sex (N) | Sex (N) | |||
| Male | 11 | 10 | Male | 13 |
| Female | 12 | 10 | Female | 7 |